SMC - July 2022 decisions

SMC

11 July 2022 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice on five new medicines.

Crizanlizumab was accepted for use in patients with sickle cell disease on an interim basis subject to ongoing evaluation and future reassessment. Sickle cell disease is a rare genetic condition where the red blood cells become sickle shaped.

Read SMC press release

Michael Wonder

Posted by:

Michael Wonder